In a significant application of its AI-based knowledge graph and data science technologies, Data2Discovery Inc has discovered a promising potential treatment for mycobacterium infections including Mycobacterium tuberculosis (MTB) and Mycobacterium Abscessus Complex (MABC). The treatment shows special promise for MABC, an increasingly impactful disease for which there is no current effective treatment.

Data2Discovery along with Indiana University Crisis Technologies Innovation Lab and two partner companies have been awarded a $2.3m contract from the US Army to create a Technology in Disaster Environments Learning Accelarator (TLA) that will use Data2Discovery’s proprietary graph technologies.

Data2Discovery is mentioned in this comprehensive list of startups using AI in drug discovery, curated by BenchSci, the world's most comprehensive AI-driven biomedical discovery platform, backed by Google’s AI fund.

In March 2017, Data2Discovery was awarded a $750,000 grant from the National Science Foundation (NSF) via the highly competitive Small Business Innovation Research (SBIR) Phase II program. The grant will support Data2Discovery's efforts to support translational and phenotypic research on vast interlinked datasets; which will include applications in Drug Repurposing, Toxicology and Safety, and Phenotypic Analysis.

The  Open PHACTS Foundation is pleased to formally announce the recent collaboration with Data2Discovery to form a Strategic Partnership. The goals of the partnership will support and continue with the Open PHACTS vision of creating a sustainable, open, interoperable information infrastructure for applied life science research and development, while advancing science for the public benefit through shared knowledge and data in life science and biomedical research.

Data2Discovery is a sponsor of the AI Applications Summit: BioPharma in Boston October 25 & 26, 2018. President & Founder Dr David Wild will be speaking on Knowledge Graphs: A transformative new approach for drug discovery.